{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:42:51Z","timestamp":1794476571673,"version":"4.9.1"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41581-026-01056-2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:22:04Z","timestamp":1770726124000},"page":"406-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimal patient care in advanced chronic kidney disease progressing to kidney failure"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-573X","authenticated-orcid":false,"given":"Christian","family":"Combe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Alencar de Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Frimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-7199","authenticated-orcid":false,"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4025-0990","authenticated-orcid":false,"given":"Abdou","family":"Niang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2996-8934","authenticated-orcid":false,"given":"Talerngsak","family":"Kanjanabuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin, A. et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 105, 684\u2013701 (2024).","journal-title":"Kidney Int."},{"key":"1056_CR3","first-page":"1","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1\u2013150 (2013).","journal-title":"Kidney Int. Suppl."},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1097\/01.ASN.0000070149.78399.CE","volume":"14","author":"HI Feldman","year":"2003","unstructured":"Feldman, H. I. et al. The chronic renal insufficiency cohort (CRIC) study: design and methods. J. Am. Soc. Nephrol. 14, S148\u2013S153 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/ndt\/gft388","volume":"29","author":"B Stengel","year":"2014","unstructured":"Stengel, B. et al. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol. Dial. Transpl. 29, 1500\u20131507 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfr456","volume":"27","author":"K-U Eckardt","year":"2012","unstructured":"Eckardt, K.-U. et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol. Dial. Transplant. 27, 1454\u20131460 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10157-017-1453-2","volume":"22","author":"J Hoshino","year":"2018","unstructured":"Hoshino, J. et al. A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: the reach-J CKD cohort study. Clin. Exp. Nephrol. 22, 309\u2013317 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12882-016-0335-2","volume":"17","author":"T Dienemann","year":"2016","unstructured":"Dienemann, T. et al. International network of chronic kidney disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. BMC Nephrol. 17, 121 (2016).","journal-title":"BMC Nephrol."},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"iii27","DOI":"10.1093\/ndt\/gfs277","volume":"27","author":"KJ Jager","year":"2012","unstructured":"Jager, K. J. et al. The EQUAL study: a European study in chronic kidney disease stage 4 patients. Nephrol. Dial. Transpl. 27, iii27\u201331 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration.","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"1056_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5873","volume":"367","author":"AK Bello","year":"2019","unstructured":"Bello, A. K. et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ 367, l5873 (2019).","journal-title":"BMJ"},{"key":"1056_CR12","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2020.09.040","volume":"5","author":"MHC van Rijn","year":"2020","unstructured":"van Rijn, M. H. C., de Pinho, N. A., Wetzels, J. F., van den Brand, J. A. J. G. & Stengel, B. Worldwide disparity in the relation between CKD prevalence and kidney failure risk. Kidney Int. Rep. 5, 2284\u20132291 (2020).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047245","volume":"11","author":"E Yeung","year":"2021","unstructured":"Yeung, E. et al. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. BMJ Open. 11, e047245 (2021).","journal-title":"BMJ Open."},{"key":"1056_CR14","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.ekir.2022.08.018","volume":"7","author":"Pinho","year":"2022","unstructured":"Pinho et al. Understanding international variations in kidney failure incidence and initiation of replacement therapy. Kidney Int. Rep. 7, 2364\u20132375 (2022).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001467","volume":"3","author":"BL Neuen","year":"2023","unstructured":"Neuen, B. L. et al. National health policies and strategies for addressing chronic kidney disease: data from the International Society of Nephrology Global Kidney Health Atlas. PLoS Glob. Public Health 3, e0001467 (2023).","journal-title":"PLoS Glob. Public Health"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.kisu.2017.10.010","volume":"8","author":"H Htay","year":"2018","unstructured":"Htay, H. et al. Global access of patients with kidney disease to health technologies and medications: findings from the global kidney health atlas project. Kidney Int. Suppl. 8, 64\u201373 (2018).","journal-title":"Kidney Int. Suppl."},{"key":"1056_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"Writing Group for the CKD Prognosis Consortium et al.","year":"2023","unstructured":"Writing Group for the CKD Prognosis Consortium et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes. JAMA 330, 1266\u20131277 (2023).","journal-title":"JAMA"},{"key":"1056_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.34067\/KID.0000000000000097","volume":"4","author":"AJ Kula","year":"2023","unstructured":"Kula, A. J., Prince, D. K., Katz, R. & Bansal, N. Mortality burden and life-years lost across the age spectrum for adults living with CKD. Kidney360 4, 615\u2013621 (2023).","journal-title":"Kidney360"},{"key":"1056_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey, A. S. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 80, 17\u201328 (2011).","journal-title":"Kidney Int."},{"key":"1056_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/bmj.39001.657755.BE","volume":"333","author":"SI Hallan","year":"2006","unstructured":"Hallan, S. I. et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 333, 1047 (2006).","journal-title":"BMJ"},{"key":"1056_CR21","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.kint.2018.01.009","volume":"93","author":"ME Grams","year":"2018","unstructured":"Grams, M. E. et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 93, 1442\u20131451 (2018).","journal-title":"Kidney Int."},{"key":"1056_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807\u201314 (2012).","journal-title":"Lancet"},{"key":"1056_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","volume":"315","author":"N Tangri","year":"2016","unstructured":"Tangri, N. et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 315, 164\u201311 (2016).","journal-title":"JAMA"},{"key":"1056_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfad263","volume":"39","author":"S Bhandari","year":"2023","unstructured":"Bhandari, S., Mehta, S., Ives, N. & Cockwell, P. Utility of 2-year kidney failure risk equation for advanced chronic kidney disease: analysis from the STOP-ACEi trial. Nephrol. Dial. Transplant. 39, 884\u2013887 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.ajkd.2021.05.018","volume":"79","author":"HU Zacharias","year":"2021","unstructured":"Zacharias, H. U. et al. A predictive model for progression of CKD to kidney failure based on routine laboratory tests. Am. J. Kidney Dis. 79, 217\u2013230.e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ekir.2022.11.023","volume":"8","author":"ZA Massy","year":"2023","unstructured":"Massy, Z. A. et al. Machine learning-based urine peptidome analysis to predict and understand mechanisms of progression to kidney failure. Kidney Int. Rep. 8, 544\u2013555 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1681\/ASN.0000000000000050","volume":"34","author":"ME Grams","year":"2023","unstructured":"Grams, M. E. et al. The kidney failure risk equation: evaluation of novel input variables including EGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J. Am. Soc. Nephrol. 34, 482\u2013494 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12882-021-02402-1","volume":"22","author":"I Ali","year":"2021","unstructured":"Ali, I., Donne, R. L. & Kalra, P. A. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 22, 194 (2021).","journal-title":"BMC Nephrol."},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2215\/CJN.03940320","volume":"15","author":"GL Hundemer","year":"2020","unstructured":"Hundemer, G. L. et al. Performance of the kidney failure risk equation by disease etiology in advanced CKD. Clin. J. Am. Soc. Nephrol. 15, 1424\u20131432 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.ajkd.2023.03.014","volume":"82","author":"CD Chu","year":"2023","unstructured":"Chu, C. D. et al. Utility of the kidney failure risk equation and estimated GFR for estimating time to kidney failure in advanced CKD. Am. J. Kidney Dis. 82, 386\u2013394.e1 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR31","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867\u20131876 (2023).","journal-title":"Nat. Med."},{"key":"1056_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","volume":"50","author":"DE Weiner","year":"2007","unstructured":"Weiner, D. E. et al. The Framingham predictive instrument in chronic kidney disease. J. Am. Coll. Cardiol. 50, 217\u2013224 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1056_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MNH.0000000000000265","volume":"25","author":"K Matsushita","year":"2016","unstructured":"Matsushita, K., Ballew, S. H. & Coresh, J. Cardiovascular risk prediction in people with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 25, 518\u2013523 (2016).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1056_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","volume":"3","author":"K Matsushita","year":"2015","unstructured":"Matsushita, K. et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 3, 514\u2013525 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1056_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100552","volume":"27","author":"K Matsushita","year":"2020","unstructured":"Matsushita, K. et al. Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. Eclinicalmedicine 27, 100552 (2020).","journal-title":"Eclinicalmedicine"},{"key":"1056_CR36","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","volume":"293","author":"MG Shlipak","year":"2005","unstructured":"Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737\u20131745 (2005).","journal-title":"JAMA"},{"key":"1056_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1681\/ASN.2021060747","volume":"33","author":"JD Bundy","year":"2022","unstructured":"Bundy, J. D. et al. Risk prediction models for atherosclerotic cardiovascular disease in patients with chronic kidney disease: the CRIC study. J. Am. Soc. Nephrol. 33, 601\u2013611 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR38","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ekir.2024.05.033","volume":"9","author":"ZA Massy","year":"2024","unstructured":"Massy, Z. A. & Drueke, T. B. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int. Rep. 9, 2608\u20132618 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneph.2010.143","volume":"6","author":"TB Dr\u00fceke","year":"2010","unstructured":"Dr\u00fceke, T. B. & Massy, Z. A. Atherosclerosis in CKD: differences from the general population. Nat. Rev. Nephrol. 6, 723\u2013735 (2010).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR40","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","volume":"25","author":"JS Lees","year":"2019","unstructured":"Lees, J. S. et al. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat. Med. 25, 1753\u20131760 (2019).","journal-title":"Nat. Med."},{"key":"1056_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38300","volume":"5","author":"JS Lees","year":"2022","unstructured":"Lees, J. S. et al. Assessment of cystatin C level for risk stratification in adults with chronic kidney disease. JAMA Netw. Open 5, e2238300 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1056_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41581-021-00518-z","volume":"18","author":"K Kalantar-Zadeh","year":"2022","unstructured":"Kalantar-Zadeh, K. et al. Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat. Rev. Nephrol. 18, 185\u2013198 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.ajkd.2024.06.011","volume":"84","author":"E Speyer","year":"2024","unstructured":"Speyer, E. et al. Symptom burden and its impact on quality of life in patients with moderate to severe CKD: the international chronic kidney disease outcomes and practice patterns study (CKDopps). Am. J. Kidney Dis. 84, 696\u2013707.e1 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR44","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1093\/ndt\/gfaa012","volume":"35","author":"F Mallamaci","year":"2020","unstructured":"Mallamaci, F., Pisano, A. & Tripepi, G. Physical activity in chronic kidney disease and the EXerCise introduction to enhance trial. Nephrol. Dial. Transplant. 35, ii18\u2013ii22 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297107","volume":"19","author":"F Curtis","year":"2024","unstructured":"Curtis, F. et al. Lifestyle interventions delivered by eHealth in chronic kidney disease: a scoping review. PLoS ONE 19, e0297107 (2024).","journal-title":"PLoS ONE"},{"key":"1056_CR46","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2589-7500(23)00204-2","volume":"6","author":"SA Greenwood","year":"2024","unstructured":"Greenwood, S. A. et al. Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK. Lancet Digit. Health 6, e23\u2013e32 (2024).","journal-title":"Lancet Digit. Health"},{"key":"1056_CR47","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.ekir.2024.08.030","volume":"9","author":"SA Greenwood","year":"2024","unstructured":"Greenwood, S. A. et al. Kidney beam \u2014 a cost-effective digital intervention to improve mental health. Kidney Int. Rep. 9, 3204\u20133217 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MNH.0000000000000673","volume":"30","author":"E Tantisattamo","year":"2021","unstructured":"Tantisattamo, E. et al. Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation. Curr. Opin. Nephrol. Hypertens. 30, 14\u201326 (2021).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1056_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12882-021-02407-w","volume":"22","author":"P Martins","year":"2021","unstructured":"Martins, P. et al. Association between physical activity and mortality in end-stage kidney disease: a systematic review of observational studies. BMC Nephrol. 22, 227 (2021).","journal-title":"BMC Nephrol."},{"key":"1056_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ndt\/gfad178","volume":"39","author":"C Zoccali","year":"2023","unstructured":"Zoccali, C., Manfredini, F., Kanbay, M. & Mallamaci, F. Intradialysis exercise in hemodialysis patients: effective but complex and costly. Nephrol. Dial. Transplant. 39, 7\u20139 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR51","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes. 9.","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes \u2014 2026. Diabetes Care 49, S183\u2013S215 (2025).","journal-title":"Diabetes Care"},{"key":"1056_CR52","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group.","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98, S1\u2013S115 (2020).","journal-title":"Kidney Int."},{"key":"1056_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1056\/NEJMe2406408","volume":"391","author":"WG Herrington","year":"2024","unstructured":"Herrington, W. G. & Haynes, R. Diabetic kidney disease \u2014 semaglutide flows into the mainstream. N. Engl. J. Med. 391, 178\u2013179 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR54","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer, I. H. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 102, 974\u2013989 (2022).","journal-title":"Kidney Int."},{"key":"1056_CR55","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc23-Srev","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed, N. A. et al. Summary of revisions: standards of care in diabetes \u2014 2023. Diabetes Care 46, S5\u2013S9 (2022).","journal-title":"Diabetes Care"},{"key":"1056_CR56","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/dc13-1870","volume":"37","author":"GL Bakris","year":"2014","unstructured":"Bakris, G. L. & Molitch, M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37, 867\u2013875 (2014).","journal-title":"Diabetes Care"},{"key":"1056_CR57","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1056\/NEJMra1700312","volume":"377","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765\u20131776 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR58","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2215\/CJN.06140522","volume":"17","author":"M Faye","year":"2022","unstructured":"Faye, M. et al. Five-year symptom trajectories in nondialysis-dependent CKD patients. Clin. J. Am. Soc. Nephrol. 17, 1588\u20131597 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2215\/CJN.06190616","volume":"12","author":"JT Kelly","year":"2017","unstructured":"Kelly, J. T. et al. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. Clin. J. Am. Soc. Nephrol. 12, 272\u2013279 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/ndt\/gfaa120","volume":"36","author":"M Burnier","year":"2020","unstructured":"Burnier, M. Sodium intake and progression of chronic kidney disease \u2014 has the time finally come to do the impossible: a prospective randomized controlled trial? Nephrol. Dial. Transplant. 36, 381\u2013384 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR61","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.3390\/ijms21134744","volume":"21","author":"S Borrelli","year":"2020","unstructured":"Borrelli, S. et al. Sodium intake and chronic kidney disease. Int. J. Mol. Sci. 21, 4744 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1056_CR62","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/ndt\/16.8.1538","volume":"16","author":"CRV Tomson","year":"2001","unstructured":"Tomson, C. R. V. Advising dialysis patients to restrict fluid intake without restricting sodium intake is not based on evidence and is a waste of time. Nephrol. Dial. Transplant. 16, 1538\u20131542 (2001).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100859","volume":"38","author":"B Afsar","year":"2024","unstructured":"Afsar, B., Afsar, R. E., Caliskan, Y. & Lentine, K. L. A holistic review of sodium intake in kidney transplant patients: more questions than answers. Transplant. Rev. 38, 100859 (2024).","journal-title":"Transplant. Rev."},{"key":"1056_CR64","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler, T. A. et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am. J. Kidney Dis. 76, S1\u2013S107 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR65","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.V651427","volume":"6","author":"D Fouque","year":"1995","unstructured":"Fouque, D. et al. Insulin-like growth factor-1 and its binding proteins during a low-protein diet in chronic renal failure. J. Am. Soc. Nephrol. 6, 1427\u20131433 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR66","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.semnephrol.2018.05.008","volume":"38","author":"AY-M Wang","year":"2018","unstructured":"Wang, A. Y.-M. et al. Precision medicine for nutritional management in end-stage kidney disease and transition to dialysis. Semin. Nephrol. 38, 383\u2013396 (2018).","journal-title":"Semin. Nephrol."},{"key":"1056_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41581-020-0297-2","volume":"16","author":"JJ Carrero","year":"2020","unstructured":"Carrero, J. J. et al. Plant-based diets to manage the risks and complications of chronic kidney disease. Nat. Rev. Nephrol. 16, 1\u201318 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR68","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.akdh.2023.07.007","volume":"30","author":"H Bakis","year":"2023","unstructured":"Bakis, H., Chauveau, P., Combe, C. & Pfirmann, P. Mediterranean diet for cardiovascular risk reduction in chronic kidney disease. Adv. Kidney Dis. Health 30, 496\u2013501 (2023).","journal-title":"Adv. Kidney Dis. Health"},{"key":"1056_CR69","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2020.10.003","volume":"77","author":"S Joshi","year":"2021","unstructured":"Joshi, S., McMacken, M. & Kalantar-Zadeh, K. Plant-based diets for kidney disease: a guide for clinicians. Am. J. Kidney Dis. 77, 287\u2013296 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR70","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2215\/CJN.0000000706","volume":"20","author":"N Goraya","year":"2025","unstructured":"Goraya, N. & Wesson, D. E. Plant-based diets across the spectrum of kidney disease. Clin. J. Am. Soc. Nephrol. 20, 1142\u20131149 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR71","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1681\/ASN.2016060656","volume":"28","author":"K Sumida","year":"2017","unstructured":"Sumida, K. et al. Constipation and Incident CKD. J. Am. Soc. Nephrol. 28, 1248\u20131258 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR72","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000777","author":"D Fouque","year":"2025","unstructured":"Fouque, D., Mafra, D. & Bellizzi, V. Dietary protein intake in CKD: quantity and quality. Clin. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.2215\/CJN.0000000777 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2215\/CJN.07800621","volume":"17","author":"AY-M Wang","year":"2022","unstructured":"Wang, A. Y.-M. et al. Assessing global kidney nutrition care. Clin. J. Am. Soc. Nephrol. 17, 38\u201352 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR74","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1093\/nutrit\/nuac026","volume":"80","author":"DE St-Jules","year":"2022","unstructured":"St-Jules, D. E. & Fouque, D. Etiology-based dietary approach for managing hyperkalemia in people with chronic kidney disease. Nutr. Rev. 80, 2198\u20132205 (2022).","journal-title":"Nutr. Rev."},{"key":"1056_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2014","unstructured":"Weir, M. R. et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. 372, 211\u2013221 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR76","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal, R. et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394, 1540\u20131550 (2019).","journal-title":"Lancet"},{"key":"1056_CR77","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2215\/CJN.09660721","volume":"17","author":"DE St-Jules","year":"2022","unstructured":"St-Jules, D. E., Clegg, D. J., Palmer, B. F. & Carrero, J.-J. Can novel potassium binders liberate people with chronic kidney disease from the low-potassium diet? Clin. J. Am. Soc. Nephrol. 17, 467\u2013472 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR78","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","volume":"43","author":"M Packer","year":"2022","unstructured":"Packer, M. Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial. Eur. Heart J. 43, 4374\u20134377 (2022).","journal-title":"Eur. Heart J."},{"key":"1056_CR79","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1681\/ASN.2020081120","volume":"32","author":"K Sumida","year":"2021","unstructured":"Sumida, K. et al. Laxative use and risk of dyskalemia in patients with advanced CKD transitioning to dialysis. J. Am. Soc. Nephrol. 32, 950\u2013959 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31\u201338 (2007).","journal-title":"Kidney Int."},{"key":"1056_CR81","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1681\/ASN.2008020159","volume":"20","author":"O Moranne","year":"2009","unstructured":"Moranne, O. et al. Timing of onset of CKD-related metabolic complications. J. Am. Soc. Nephrol. 20, 164\u2013171 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrneph.2017.52","volume":"13","author":"C Zoccali","year":"2017","unstructured":"Zoccali, C. et al. The systemic nature of CKD. Nat. Rev. Nephrol. 13, 1\u201315 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100912","volume":"6","author":"M Costes-Albrespic","year":"2024","unstructured":"Costes-Albrespic, M. et al. Antihypertensive treatment patterns in CKD stages 3 and 4: the CKD-REIN Cohort Study. Kidney Med. 6, 100912 (2024).","journal-title":"Kidney Med."},{"key":"1056_CR84","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2019.04.032","volume":"96","author":"Pinho","year":"2019","unstructured":"Pinho et al. Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. Kidney Int. 96, 983\u2013994 (2019).","journal-title":"Kidney Int."},{"key":"1056_CR85","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","volume":"72","author":"MR Weir","year":"2018","unstructured":"Weir, M. R. et al. Use of renin-angiotensin system blockade in advanced CKD: an NKF-KDOQI controversies report. Am. J. Kidney Dis. 72, 873\u2013884 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR86","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMe2214315","volume":"387","author":"JR Ingelfinger","year":"2022","unstructured":"Ingelfinger, J. R. Discontinuation of RAS inhibitors in advanced CKD \u2014 has equipoise occurred? N. Engl. J. Med. 387, 2083\u20132084 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR87","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung, A. K. et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 99, 559\u2013569 (2021).","journal-title":"Kidney Int."},{"key":"1056_CR88","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","volume":"79","author":"D Pugh","year":"2019","unstructured":"Pugh, D., Gallacher, P. J. & Dhaun, N. Management of hypertension in chronic kidney disease. Drugs 79, 365\u2013379 (2019).","journal-title":"Drugs"},{"key":"1056_CR89","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/jch.13563","volume":"21","author":"R Pecoits-Filho","year":"2019","unstructured":"Pecoits-Filho, R. et al. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J. Clin. Hypertens. 21, 337\u201311 (2019).","journal-title":"J. Clin. Hypertens."},{"key":"1056_CR90","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari, S. et al. Renin\u2013angiotensin system inhibition in advanced chronic kidney disease. N. Engl. J. Med. 387, 2021\u20132032 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR91","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"EL Fu","year":"2021","unstructured":"Fu, E. L. et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J. Am. Soc. Nephrol. 32, 424\u2013435 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR92","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.kint.2018.03.013","volume":"94","author":"A Karaboyas","year":"2018","unstructured":"Karaboyas, A. et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 94, 589\u2013598 (2018).","journal-title":"Kidney Int."},{"key":"1056_CR93","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.ajkd.2023.01.444","volume":"82","author":"DA Bushinsky","year":"2023","unstructured":"Bushinsky, D. A. et al. Patiromer treatment in patients with CKD, hyperkalemia, and hyperphosphatemia: a post hoc analysis of 3 clinical trials. Am. J. Kidney Dis. 82, 97\u2013104 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi, Q. et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 381, e074068 (2023).","journal-title":"BMJ."},{"key":"1056_CR95","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2215\/CJN.0000000000000258","volume":"18","author":"J Rangaswami","year":"2023","unstructured":"Rangaswami, J. & Mathew, R. O. Reducing kidney disease burden in type 2 diabetes with SGLT2 inhibitors: shifting the goalposts upstream. Clin. J. Am. Soc. Nephrol. 18, 1119\u20131121 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR96","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald, E. Gliflozins in the management of cardiovascular disease. N. Engl. J. Med. 386, 2024\u20132034 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR97","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819\u2013829 (2020).","journal-title":"Lancet"},{"key":"1056_CR98","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22\u201331 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1056_CR99","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR100","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"EMPA-KIDNEY Collaborative Group. et al.","year":"2025","unstructured":"EMPA-KIDNEY Collaborative Group. et al. Long-term effects of empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 392, 777\u2013787 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR101","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group. et al.","year":"2022","unstructured":"The EMPA-KIDNEY Collaborative Group. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117\u2013127 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR102","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215\u2013224 (2021).","journal-title":"Kidney Int."},{"key":"1056_CR103","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1\u2013S127 (2022).","journal-title":"Kidney Int."},{"key":"1056_CR104","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.ekir.2023.05.001","volume":"8","author":"T Singh","year":"2023","unstructured":"Singh, T., Li, T., Mandebrot, D., Astor, B. C. & Mehr, A. P. Prescribing patterns for sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): a survey of nephrologists. Kidney Int. Rep. 8, 1669\u20131671 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR105","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMe2500233","volume":"392","author":"DE Leaf","year":"2025","unstructured":"Leaf, D. E. & Bansal, N. Another win for SGLT2 inhibitors in chronic kidney disease. N. Engl. J. Med. 392, 822\u2013823 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR106","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","volume":"18","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L., Berger, S., Gansevoort, R. T. on behalf of the Renal Life Cycle Trial Investigators. Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation. Clin. J. Am. Soc. Nephrol. 18, 1500\u20131502 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR107","doi-asserted-by":"publisher","first-page":"693","DOI":"10.7326\/M23-1874","volume":"177","author":"F-S Yen","year":"2024","unstructured":"Yen, F.-S. et al. Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease. Ann. Intern. Med. 177, 693\u2013700 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1056_CR108","doi-asserted-by":"publisher","first-page":"101627","DOI":"10.1016\/j.diabet.2025.101627","volume":"51","author":"TD Cohen","year":"2025","unstructured":"Cohen, T. D. et al. Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus. Diabetes Metab. 51, 101627 (2025).","journal-title":"Diabetes Metab."},{"key":"1056_CR109","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MNH.0000000000000976","volume":"33","author":"MW Holliday","year":"2024","unstructured":"Holliday, M. W., Frost, L. & Navaneethan, S. D. Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr. Opin. Nephrol. Hypertens. 33, 331\u2013336 (2024).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1056_CR110","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR111","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278\u2013285 (2024).","journal-title":"Nat. Med."},{"key":"1056_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70144","volume":"39","author":"H Zelada","year":"2025","unstructured":"Zelada, H. et al. Efficacy, tolerability, and safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) in kidney transplant recipients with diabetes. Clin. Transplant. 39, e70144 (2025).","journal-title":"Clin. Transplant."},{"key":"1056_CR113","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.diabet.2025.101624","volume":"51","author":"TD Cohen","year":"2025","unstructured":"Cohen, T. D. et al. Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus. Diabetes Metab. 51, 101624 (2025).","journal-title":"Diabetes Metab."},{"key":"1056_CR114","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.3390\/jcm13206181","volume":"13","author":"I Bellos","year":"2024","unstructured":"Bellos, I., Lagiou, P., Benetou, V. & Marinaki, S. Safety and efficacy of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney transplant recipients: synthesis of evidence. J. Clin. Med. 13, 6181 (2024).","journal-title":"J. Clin. Med."},{"key":"1056_CR115","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12933-024-02364-2","volume":"23","author":"H-W Lai","year":"2024","unstructured":"Lai, H.-W., See, C. Y., Chen, J.-Y. & Wu, V.-C. Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists. Cardiovasc. Diabetol. 23, 277 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1056_CR116","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.japh.2023.06.003","volume":"63","author":"AM Thomas","year":"2023","unstructured":"Thomas, A. M., Lamb, K. & Howard, O. Glucagon-like peptide-1 receptor agonists use for type 2 diabetes mellitus in end-stage renal disease. J. Am. Pharm. Assoc. 63, 1612\u20131616 (2023).","journal-title":"J. Am. Pharm. Assoc."},{"key":"1056_CR117","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.0000000750","volume":"20","author":"BJ Orandi","year":"2025","unstructured":"Orandi, B. J. et al. GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis. Clin. J. Am. Soc. Nephrol. 20, 1100\u20131110 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR118","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal, R. et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N. Engl. J. Med. 385, 2507\u20132519 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR119","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.0000000000000484","volume":"19","author":"R Agarwal","year":"2024","unstructured":"Agarwal, R., Sinha, A. D. & Tu, W. Mechanisms of antihypertensive effect of chlorthalidone in advanced chronic kidney disease. Clin. J. Am. Soc. Nephrol. 19, 1025\u20131032 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR120","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2215\/CJN.0000000000000520","volume":"19","author":"TH Jafar","year":"2024","unstructured":"Jafar, T. H. & Feng, L. Understanding the BP-lowering mechanism of chlorthalidone in advanced kidney disease. Clin. J. Am. Soc. Nephrol. 19, 949\u2013951 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR121","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41581-024-00918-x","volume":"21","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R., Verma, A. & Georgianos, P. I. Diuretics in patients with chronic kidney disease. Nat. Rev. Nephrol. 21, 264\u2013278 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR122","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.kint.2023.05.024","volume":"104","author":"A-L Faucon","year":"2023","unstructured":"Faucon, A.-L. et al. A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality. Kidney Int. 104, 542\u2013551 (2023).","journal-title":"Kidney Int."},{"key":"1056_CR123","doi-asserted-by":"publisher","first-page":"sfae141","DOI":"10.1093\/ckj\/sfae141","volume":"17","author":"N Tabibzadeh","year":"2024","unstructured":"Tabibzadeh, N. et al. Diuretic prescriptions in the first year of haemodialysis: international practice patterns and associations with outcomes. Clin. Kidney J. 17, sfae141 (2024).","journal-title":"Clin. Kidney J."},{"key":"1056_CR124","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","volume":"18","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis, P. et al. Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes. Clin. J. Am. Soc. Nephrol. 18, 602\u2013612 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR125","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.ekir.2019.07.014","volume":"4","author":"ZA Massy","year":"2019","unstructured":"Massy, Z. A. et al. Achievement of low-density lipoprotein cholesterol targets in CKD. Kidney Int. Rep. 4, 1546\u20131554 (2019).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR126","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40620-021-01086-y","volume":"34","author":"ZA Massy","year":"2021","unstructured":"Massy, Z. A. et al. Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study. J. Nephrol 34, 1467\u20131477\u00a0(2021).","journal-title":"J. Nephrol"},{"key":"1056_CR127","unstructured":"KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl. 3, 1\u201356 (2013)."},{"key":"1056_CR128","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2215\/CJN.12620921","volume":"17","author":"ZA Massy","year":"2022","unstructured":"Massy, Z. A. et al. Association of serum phosphate with efficacy of statin therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 17, 546\u2013554 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR129","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181\u20132192 (2011).","journal-title":"Lancet"},{"key":"1056_CR130","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ekir.2023.07.032","volume":"8","author":"M Canney","year":"2023","unstructured":"Canney, M. et al. Regional variation in hemoglobin distribution among individuals with CKD: the ISN International Network of CKD Cohorts. Kidney Int. Rep. 8, 2056\u20132067 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR131","unstructured":"KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 179 (2012)."},{"key":"1056_CR132","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","volume":"62","author":"AS Kliger","year":"2013","unstructured":"Kliger, A. S. et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am. J. Kidney Dis. 62, 849\u2013859 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR133","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli, F. et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol. Dial. Transplant. 28, 1346\u20131359 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR134","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","volume":"26","author":"S Bhandari","year":"2025","unstructured":"Bhandari, S. et al. UK Kidney Association clinical practice guideline: update of anaemia of chronic kidney disease. BMC Nephrol. 26, 193 (2025).","journal-title":"BMC Nephrol."},{"key":"1056_CR135","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/s41598-020-79254-6","volume":"11","author":"MB Lopes","year":"2021","unstructured":"Lopes, M. B. et al. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci. Rep. 11, 1784 (2021).","journal-title":"Sci. Rep."},{"key":"1056_CR136","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2020101531","volume":"32","author":"M Guedes","year":"2021","unstructured":"Guedes, M. et al. Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia. J. Am. Soc. Nephrol. 32, 2020\u20132030 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR137","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ndt\/gfad235","volume":"39","author":"LL Gall","year":"2023","unstructured":"Gall, L. L. et al. Haemoglobin trajectories in chronic kidney disease and risk of major adverse cardiovascular events. Nephrol. Dial. Transplant. 39, 669\u2013682 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR138","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1681\/ASN.2022040413","volume":"33","author":"F Locatelli","year":"2022","unstructured":"Locatelli, F. & Vecchio, L. D. Hypoxia-inducible factor\u2013prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs? J. Am. Soc. Nephrol. 33, 1966\u20131979 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR139","doi-asserted-by":"crossref","unstructured":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7, 1\u201359 (2017).","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"1056_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115058","volume":"129","author":"S Liabeuf","year":"2019","unstructured":"Liabeuf, S. et al. International variation in the management of mineral bone disorder in patients with chronic kidney disease: results from CKDopps. Bone 129, 115058 (2019).","journal-title":"Bone"},{"key":"1056_CR141","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/15269248231189880","volume":"33","author":"H Sweiss","year":"2023","unstructured":"Sweiss, H. et al. Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients. Prog. Transpl. 33, 261\u2013265 (2023).","journal-title":"Prog. Transpl."},{"key":"1056_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05374291 (2025)."},{"key":"1056_CR143","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S233197","volume":"12","author":"A Karaboyas","year":"2020","unstructured":"Karaboyas, A. et al. Estimating the fraction of first-year hemodialysis deaths attributable to potentially modifiable risk factors: results from the DOPPS. Clin. Epidemiol. 12, 51\u201360 (2020).","journal-title":"Clin. Epidemiol."},{"key":"1056_CR144","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","volume":"18","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Ma, X., Zheng, J., Jia, J. & Yan, T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol. 18, 206 (2017).","journal-title":"BMC Nephrol."},{"key":"1056_CR145","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","volume":"18","author":"J Barreto","year":"2023","unstructured":"Barreto, J. et al. Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 18, 1051\u20131058 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR146","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","volume":"406","author":"M Walsh","year":"2025","unstructured":"Walsh, M. et al. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet 406, 695\u2013704 (2025).","journal-title":"Lancet"},{"key":"1056_CR147","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","volume":"406","author":"P Rossignol","year":"2025","unstructured":"Rossignol, P. et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 406, 705\u2013718 (2025).","journal-title":"Lancet"},{"key":"1056_CR148","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ndt\/gfv378","volume":"31","author":"D Abramowicz","year":"2016","unstructured":"Abramowicz, D. et al. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes working group and ERBP. Nephrol. Dial. Transplant. 31, 691\u2013697 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR149","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1046\/j.1523-1755.2000.00287.x","volume":"58","author":"H-U Meier-Kriesche","year":"2000","unstructured":"Meier-Kriesche, H.-U. et al. Effect of waiting time on renal transplant outcome. Kidney Int. 58, 1311\u20131317 (2000).","journal-title":"Kidney Int."},{"key":"1056_CR150","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJM200103083441004","volume":"344","author":"KC Mange","year":"2001","unstructured":"Mange, K. C., Joffe, M. M. & Feldman, H. I. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N. Engl. J. Med. 344, 726\u2013731 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR151","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ndt\/gfy039","volume":"34","author":"M Prezelin-Reydit","year":"2018","unstructured":"Prezelin-Reydit, M. et al. Prolonged dialysis duration is associated with graft failure and mortality after kidney transplantation: results from the French transplant database. Nephrol. Dial. Transpl. 34, 538\u2013545 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR152","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2215\/CJN.08670815","volume":"11","author":"N Goto","year":"2016","unstructured":"Goto, N. et al. Association of dialysis duration with outcomes after transplantation in a Japanese cohort. Clin. J. Am. Soc. Nephrol. 11, 497\u2013504 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR153","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34971","volume":"5","author":"S Strohmaier","year":"2022","unstructured":"Strohmaier, S. et al. Survival benefit of first single-organ deceased donor kidney transplantation compared with long-term dialysis across ages in transplant-eligible patients with kidney failure. JAMA Netw. Open 5, e2234971 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1056_CR154","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1681\/ASN.2019030242","volume":"30","author":"F McCormick","year":"2019","unstructured":"McCormick, F., Held, P. J., Chertow, G. M., Peters, T. G. & Roberts, J. P. Removing disincentives to kidney donation: a quantitative analysis. J. Am. Soc. Nephrol. 30, 1349\u20131357 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR155","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/ajt.13490","volume":"16","author":"PJ Held","year":"2015","unstructured":"Held, P. J., McCormick, F., Ojo, A. & Roberts, J. P. A cost-benefit analysis of government compensation of kidney donors. Am. J. Transpl. 16, 877\u2013885 (2015).","journal-title":"Am. J. Transpl."},{"key":"1056_CR156","unstructured":"REIN annual report 2021: summary. https:\/\/www.agence-biomedecine.fr\/IMG\/pdf\/rapport_rein_2021_2023-06-26.pdf (2023)."},{"key":"1056_CR157","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5527\/wjn.v12.i3.40","volume":"12","author":"RA Gadelkareem","year":"2023","unstructured":"Gadelkareem, R. A. et al. Preemptive living donor kidney transplantation: access, fate, and review of the status in Egypt. World J. Nephrol. 12, 40\u201355 (2023).","journal-title":"World J. Nephrol."},{"key":"1056_CR158","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41581-025-01019-z","volume":"21","author":"DS Shah","year":"2025","unstructured":"Shah, D. S. Insights from Nepal into implementing transplantation programmes in low-resource settings. Nat. Rev. Nephrol. 21, 812 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR159","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ndt\/gfaa026","volume":"36","author":"L Cheddani","year":"2020","unstructured":"Cheddani, L. et al. Higher mortality risk among kidney transplant recipients than among estimated glomerular filtration rate-matched patients with CKD \u2014 preliminary results. Nephrol. Dial. Transplant. 36, 176\u2013184 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1056_CR160","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe, R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725\u20131730 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1056_CR161","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jama.2019.12803","volume":"322","author":"JC Gander","year":"2019","unstructured":"Gander, J. C. et al. Association between dialysis facility ownership and access to kidney transplantation. JAMA 322, 957 (2019).","journal-title":"JAMA"},{"key":"1056_CR162","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2019.01.017","volume":"96","author":"CT Chan","year":"2019","unstructured":"Chan, C. T. et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 96, 37\u201347 (2019).","journal-title":"Kidney Int."},{"key":"1056_CR163","volume":"2024","author":"MS Cheetham","year":"2024","unstructured":"Cheetham, M. S. et al. Home versus in-centre haemodialysis for people with kidney failure. Cochrane Database Syst. Rev. 2024, CD009535 (2024).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1056_CR164","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/ndt\/gfab170","volume":"36","author":"V Fages","year":"2021","unstructured":"Fages, V. et al. Urgent-start dialysis in patients referred early to a nephrologist \u2014 the CKD-REIN prospective cohort study. Nephrol. Dial. Transpl. 36, 1500\u20131510 (2021).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR165","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ki.2013.252","volume":"85","author":"BM Robinson","year":"2014","unstructured":"Robinson, B. M. et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int. 85, 158\u2013165 (2014).","journal-title":"Kidney Int."},{"key":"1056_CR166","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","volume":"75","author":"CE Lok","year":"2020","unstructured":"Lok, C. E. et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am. J. Kidney Dis. 75, S1\u2013S164 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR167","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.ajkd.2020.06.020","volume":"77","author":"RL Pisoni","year":"2021","unstructured":"Pisoni, R. L. et al. International comparisons of native arteriovenous fistula patency and time to becoming catheter-free: findings from the dialysis outcomes and practice patterns study (DOPPS). Am. J. Kidney Dis. 77, 245\u2013254 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR168","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1053\/j.ajkd.2008.10.043","volume":"53","author":"RL Pisoni","year":"2009","unstructured":"Pisoni, R. L. et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am. J. Kidney Dis. 53, 475\u2013491 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR169","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21804\/26-1-5381","volume":"26","author":"M Faye","year":"2023","unstructured":"Faye, M. et al. Vascular access in Senegalese patients starting chronic haemodialysis. Afr. J. Nephrol. 26, 3\u20138, https:\/\/doi.org\/10.21804\/26-1-5381 (2023).","journal-title":"Afr. J. Nephrol."},{"key":"1056_CR170","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ndt\/gfu293","volume":"30","author":"C Couchoud","year":"2015","unstructured":"Couchoud, C. et al. Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence. Nephrol. Dial. Transpl. 30, 310\u2013320 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR171","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gfu390","volume":"30","author":"C Combe","year":"2015","unstructured":"Combe, C., Rigothier, C. & Chauveau, P. Evidence-based choice of dialysis technique in diabetics with end-stage kidney disease: half a loaf is better than no bread. Nephrol. Dial. Transpl. 30, 160\u2013162 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR172","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.7326\/M23-3028","volume":"177","author":"ME Montez-Rath","year":"2024","unstructured":"Montez-Rath, M. E. et al. Effect of starting dialysis versus continuing medical management on survival and home time in older adults with kidney failure: a target trial emulation study. Ann. Intern. Med. 177, 1233\u20131243 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1056_CR173","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1093\/ndt\/gfac205","volume":"37","author":"DA Jaques","year":"2022","unstructured":"Jaques, D. A. et al. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis. Nephrol. Dial. Transpl. 37, 2514\u20132521 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR174","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.kint.2022.01.007","volume":"101","author":"C Wanner","year":"2022","unstructured":"Wanner, C., Lopau, K. & Haberstroh, H. The safety and feasibility of incremental dialysis must be proven before its widespread use. Kidney Int. 101, 468\u2013471 (2022).","journal-title":"Kidney Int."},{"key":"1056_CR175","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.kint.2025.03.032","volume":"108","author":"M Murea","year":"2025","unstructured":"Murea, M. et al. From niche to norm: a multi-action plan to close gaps and mainstream incremental hemodialysis. Kidney Int. 108, 201\u2013213 (2025).","journal-title":"Kidney Int."},{"key":"1056_CR176","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.ajkd.2022.05.016","volume":"81","author":"MJ Elliott","year":"2023","unstructured":"Elliott, M. J. et al. Patient and clinician perspectives on shared decision making in vascular access selection: a qualitative study. Am. J. Kidney Dis. 81, 48\u201358.e1 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR177","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1053\/j.ajkd.2014.12.014","volume":"65","author":"RL Pisoni","year":"2015","unstructured":"Pisoni, R. L., Zepel, L., Port, F. K. & Robinson, B. M. Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am. J. Kidney Dis. 65, 905\u2013915 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR178","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ekir.2021.11.018","volume":"7","author":"M Hecking","year":"2021","unstructured":"Hecking, M. et al. Sex-specific differences in mortality and incident dialysis in the chronic kidney disease outcomes and practice patterns study. Kidney Int. Rep. 7, 410\u2013423 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1056_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181254","volume":"12","author":"NA de Pinho","year":"2017","unstructured":"de Pinho, N. A. et al. Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: a registry-based study. PLoS ONE 12, e0181254 (2017).","journal-title":"PLoS ONE"},{"key":"1056_CR180","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.xkme.2019.10.011","volume":"2","author":"K Griva","year":"2020","unstructured":"Griva, K. et al. Patient-related barriers to timely dialysis access preparation: a qualitative study of the perspectives of patients, family members, and health care providers. Kidney Med. 2, 29\u201341 (2020).","journal-title":"Kidney Med."},{"key":"1056_CR181","doi-asserted-by":"publisher","first-page":"708","DOI":"10.34067\/KID.0007812020","volume":"2","author":"JE Flythe","year":"2021","unstructured":"Flythe, J. E. et al. Targeting patient and health system barriers to improve rates of hemodialysis initiation with an arteriovenous access. Kidney360 2, 708\u2013720 (2021).","journal-title":"Kidney360"},{"key":"1056_CR182","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.ajkd.2010.12.020","volume":"57","author":"PA Lopez-Vargas","year":"2011","unstructured":"Lopez-Vargas, P. A. et al. Barriers to timely arteriovenous fistula creation: a study of providers and patients. Am. J. Kidney Dis. 57, 873\u2013882 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"1056_CR183","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1681\/ASN.0000000000000443","volume":"35","author":"A-H Tabcheh","year":"2024","unstructured":"Tabcheh, A.-H. et al. Arteriovenous access creation and eGFR decline in patients with CKD. J. Am. Soc. Nephrol. 35, 1570\u20131573 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR184","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0896860819895364","volume":"40","author":"EA Brown","year":"2020","unstructured":"Brown, E. A. et al. International Society for Peritoneal Dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit. Dial. Int. 40, 244\u2013253 (2020).","journal-title":"Perit. Dial. Int."},{"key":"1056_CR185","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/ki.2015.110","volume":"88","author":"SN Davison","year":"2015","unstructured":"Davison, S. N. et al. Executive summary of the KDIGO controversies conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care. Kidney Int. 88, 447\u2013459 (2015).","journal-title":"Kidney Int."},{"key":"1056_CR186","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.kint.2023.10.001","volume":"105","author":"SN Davison","year":"2024","unstructured":"Davison, S. N. et al. Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure. Kidney Int. 105, 35\u201345 (2024).","journal-title":"Kidney Int."},{"key":"1056_CR187","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41581-024-00871-9","volume":"20","author":"RD McMahan","year":"2024","unstructured":"McMahan, R. D. & Sudore, R. L. Making advance care planning easier for adults with kidney disease and their clinicians. Nat. Rev. Nephrol. 20, 564\u2013565 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1056_CR188","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/ndt\/gfad088","volume":"38","author":"A Hamroun","year":"2023","unstructured":"Hamroun, A., Glowacki, F. & Frimat, L. Comprehensive conservative care: what doctors say, what patients hear. Nephrol. Dial. Transpl. 38, 2428\u20132443 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR189","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.2215\/CJN.01740218","volume":"13","author":"K Ladin","year":"2018","unstructured":"Ladin, K. et al. Characterizing approaches to dialysis decision making with older adults: a qualitative study of nephrologists. Clin. J. Am. Soc. Nephrol. 13, 1188\u20131196 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR190","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042548","volume":"10","author":"HO Hounkpatin","year":"2020","unstructured":"Hounkpatin, H. O. et al. Patients\u2019 and kidney care team\u2019s perspectives of treatment burden and capacity in older people with chronic kidney disease: a qualitative study. BMJ Open. 10, e042548 (2020).","journal-title":"BMJ Open."},{"key":"1056_CR191","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/ndt\/gfac009","volume":"37","author":"A Hamroun","year":"2022","unstructured":"Hamroun, A. et al. Barriers to conservative care from patients\u2019 and nephrologists\u2019 perspectives: the CKD-REIN study. Nephrol. Dial. Transpl. 37, 2438\u20132448 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1056_CR192","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2215\/CJN.11861115","volume":"11","author":"RL Morton","year":"2016","unstructured":"Morton, R. L. et al. Conservative management and end-of-life care in an Australian cohort with ESRD. Clin. J. Am. Soc. Nephrol. 11, 2195\u20132203 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1056_CR193","doi-asserted-by":"crossref","unstructured":"Jain, G. & Weiner, D. E. Value-based care in nephrology: the kidney care choices model and other reforms. https:\/\/innovation.cms.gov\/innovation-models\/kidney-care-choices-kcc-model (2021).","DOI":"10.34067\/KID.0004552021"},{"key":"1056_CR194","unstructured":"Centers for Medicare & Medicaid Services. ESRD treatment choices (ETC) model. https:\/\/innovation.cms.gov\/innovation-models\/esrd-treatment-choices-model (2025)."},{"key":"1056_CR195","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1681\/ASN.2022060716","volume":"34","author":"E Lin","year":"2023","unstructured":"Lin, E., Dave, G. & Kshirsagar, A. V. The new kidney-focused companies: a privatized approach to value-based care and addressing social determinants of health. J. Am. Soc. Nephrol. 34, 17\u201320 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR196","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10754-007-9025-8","volume":"7","author":"I Durand-Zaleski","year":"2007","unstructured":"Durand-Zaleski, I., Combe, C. & Lang, P. International study of health care organization and financing for end-stage renal disease in France. Int. J. Health Care Finance Econ. 7, 171\u2013183 (2007).","journal-title":"Int. J. Health Care Finance Econ."},{"key":"1056_CR197","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1681\/ASN.2011111094","volume":"23","author":"R Vanholder","year":"2012","unstructured":"Vanholder, R. et al. Reimbursement of dialysis: a comparison of seven countries. J. Am. Soc. Nephrol. 23, 1291\u20131298 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1056_CR198","unstructured":"Arr\u00eat\u00e9 du 25 septembre 2019 relatif aux forfaits allou\u00e9s aux \u00e9tablissements de sant\u00e9 dans le cadre de la prise en charge de patients atteints de maladie r\u00e9nale chronique en application de l\u2019article L. 162-22-6-2 du code de la s\u00e9curit\u00e9 sociale. Journal Officiel de la R\u00e9publique Fran\u00e7aise (2019)."},{"key":"1056_CR199","unstructured":"Bello, A. et al. ISN \u2014 global kidney health atlas: a report by the International Society of Nephrology: an assessment of global kidney health care status focussing on capacity, availability, accessibility, affordability and outcomes of kidney disease. https:\/\/www.theisn.org\/wp-content\/uploads\/media\/ISN%20Atlas_2023%20Digital.pdf (2023)."},{"key":"1056_CR200","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kisu.2017.10.008","volume":"8","author":"AK Bello","year":"2018","unstructured":"Bello, A. K. et al. Global overview of health systems oversight and financing for kidney care. Kidney Int. Suppl. 8, 41\u201351 (2018).","journal-title":"Kidney Int. Suppl."},{"key":"1056_CR201","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/nep.13935","volume":"26","author":"IG Okpechi","year":"2021","unstructured":"Okpechi, I. G. et al. Building optimal and sustainable kidney care in low resource settings: the role of healthcare systems. Nephrology 26, 948\u2013960 (2021).","journal-title":"Nephrology"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01056-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:01:54Z","timestamp":1779451314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01056-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":201,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01056-2","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"15 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}